The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...

FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday ​that a late-stage trial testing ‌its multiple sclerosis drug ...

In a new study, researchers found that increased expression of gene PRDM1-S triggers loss of immune regulation in autoimmune conditions like multiple sclerosis (MS). The findings could pave the way ...

The company is evaluating the use of fully human intranasal anti-CD3 monoclonal antibody foralumab for the treatment of patients with Secondary Progressive Multiple Sclerosis in a phase 2a study. The ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Progentos' CEO is also the co ...

(Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a ...

FRANKFURT, Jan 13 (Reuters) - Merck KGaA said on Tuesday it had bought the rights to develop and market an experimental multiple sclerosis (MS) drug from British biotech company Apitope, expanding its ...

Antibodies that deplete B cells might hold the key to protecting both white and gray matter in the brain against the debilitating effects of multiple sclerosis (MS), according to recent research ...

BOSTON (Reuters) - Genzyme Corp presented new data from a trial of its experimental multiple sclerosis drug alemtuzumab on Thursday that continued to show strong efficacy with no new or worsening side ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...